Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update
Traws Pharma, Inc. (TRAW)
Company Research
Source: GlobeNewswire
Completed acquisition of Trawsfynydd and concurrent $14 million Capital Raise Excellent pipeline progress, led by candidates for COVID 19, influenza, and oncology programs Poised to initiate Phase 2 studies in H2 2024 for our influenza candidate and ritonavir-free COVID 19 protease inhibitor NEWTOWN, Pa., May 16, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral diseases and cancer, today announced financial results for the first quarter of 2024, and provided a business update. “2024 has already been a transformative year for Traws Pharma to advance our portfolio of novel treatments for serious respiratory infections and oncology programs. We completed the acquisition of Trawsfynydd and concluded a concurrent $14 million private placement financing. In addition, we initiated first-in-human dosing for our COVID 19 product candidate, including completion of the
Show less
Read more
Impact Snapshot
Event Time:
TRAW
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRAW alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRAW alerts
High impacting Traws Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
TRAW
News
- Traws Pharma’s ICAR Poster Highlights Potency of COVID-19 CandidateGlobeNewswire
- Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID TherapyGlobeNewswire
- HanxBio announces the publication of a research paper in Scientific Reports on preclinical evaluation of Narazaciclib for the treatment of acute myeloid leukemia (AML) [Yahoo! Finance]Yahoo! Finance
TRAW
Earnings
- 5/15/24 - In-Line
TRAW
Sec Filings
- 6/21/24 - Form 8-K
- 6/20/24 - Form 4
- 6/17/24 - Form 8-K/A
- TRAW's page on the SEC website